<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744445</url>
  </required_header>
  <id_info>
    <org_study_id>022-1994</org_study_id>
    <nct_id>NCT00744445</nct_id>
  </id_info>
  <brief_title>Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity</brief_title>
  <official_title>Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study was to determine if the activity of erythropoietin
      (r-HuEPO) is time dependent when given to chronic renal failure patients at three different
      times of day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase-II crossover study was designed to test if the activity of erythropoietin is time
      dependent. Patients with chronic renal failure on hemodialysis requiring r-HuEPO to maintain
      adequate levels of hematocrit are eligible for the study. Patients were administered r-HuEPO
      subcutaneously three times per week, 50 U/kg, rounded to the nearest 2000 units. r-HuEPO will
      be administered until the hematocrit rises from the baseline level of 20-24% to the target
      level of 30-34%. This will be repeated three times, each at different times of day, either
      0800, 1500 or 2200 hrs and the order of these will be randomly determined. Each patient will
      complete all three of the phases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1993</start_date>
  <completion_date type="Actual">August 1998</completion_date>
  <primary_completion_date type="Actual">August 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for hematocrit to rise</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Chronic Renal Failure</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>0800</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>r-HuEPO administered at 0800 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>r-HuEPO administered at 1500 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>r-HuEPO administered at 2200 hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-HuEPO</intervention_name>
    <description>r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.</description>
    <arm_group_label>0800</arm_group_label>
    <arm_group_label>1500</arm_group_label>
    <arm_group_label>2200</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic renal failure patients requiring hemodialysis and requiring r-HuEPO to
             maintain adequate hematocrit levels

          -  Serum ferritin level &gt; 200 micrograms/L and transferrin saturation &gt; 15%

          -  Serum erythropoietin level less than 500 mu/ml (when off r-HuEPO)

          -  Prior therapy with r-HuEPO

          -  An adequate program of dialysis established

          -  Informed consent signed

        Exclusion Criteria:

          -  Adocumented cause of anemia other than chronic renal disease

          -  Symptoms of unstable coronary artery disease

          -  Poorly controled hypertension

          -  Known seizure disorder

          -  Other active inflammatory or infective disorders

          -  Other disorders that may diminish the response of the bone marrow to r-HuEPO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Bjarnason, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2008</study_first_posted>
  <last_update_submitted>August 29, 2008</last_update_submitted>
  <last_update_submitted_qc>August 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. G.A. Bjarnason</name_title>
    <organization>Sunnybrook Health Sciences Centre</organization>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

